SleepCited

Suppressive effect of Yokukansan on excessive release of glutamate and aspartate in the hippocampus of zinc-deficient rats.

Atsushi Takeda, Hiromasa Itoh, Haruna Tamano, Mitsutoshi Yuzurihara, Naoto Oku
Other Nutritional neuroscience 2008 73 Zitierungen

Studiendesign

Studientyp
In Vitro
Population
Zinc-deficient rat model (animal study)
Intervention
Suppressive effect of Yokukansan on excessive release of glutamate and aspartate in the hippocampus of zinc-deficient rats. not specified
Vergleichsgruppe
zinc-deficient control rats (no Yokukansan)
Primärer Endpunkt
Extracellular concentrations of glutamate and aspartate in hippocampus after KCl stimulation
Wirkungsrichtung
Positive
Verzerrungsrisiko
Unclear

Abstract

Yokukansan (TJ-54), a herbal medicine, has been used as a cure for insomnia and irritability in children. Yokukansan also improves behavioral and psychological symptoms such as agitation, aggression and irritability in patients with dementia including Alzheimer's disease, in which the glutamatergic neurotransmitter system is perturbed. However, the action of Yokukansan in synaptic neurotransmission is unknown. In the present study, the action of Yokukansan in the glutamatergic neurotransmitter system was examined in zinc-deficient rats, a neurological disease model, in which the glutamatergic neurotransmitter system is perturbed. Administration of Yokukansan significantly suppressed the increase in extracellular concentrations of glutamate and aspartate in the hippocampus after stimulation with 100 mM KCl, but not the increase in extracellular concentrations of glycine and taurine, suggesting that Yokukansan is involved in modulation of excitatory neurotransmitter systems. The present study demonstrates that Yokukansan is a possible medicine for prevention or cure of neurological diseases associated with excitotoxicity.

Zusammenfassung

Yokukansan is a possible medicine for prevention or cure of neurological diseases associated with excitotoxicity and is involved in modulation of excitatory neurotransmitter systems.

Verwendet in Evidenzbewertungen